The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis.

Authors:
Cuijpers P; Karyotaki E; Ciharova M; Miguel C; Noma H and 1 more

Journal:
Acta Psychiatr Scand

Publication Year: 2021

DOI:
10.1111/acps.13335

PMCID:
PMC8457213

PMID:
34107050

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Psychiatr Scand

Abbreviation: Acta Psychiatr Scand

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Psychiatry

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.
Strawbridge R; Kurana S; Kerr-Gaffney J and 4 more (2022) - Transparency Score: 3/6
Autism and self-harm: A population-based and discordant sibling study of young individuals.
Stark I; Rai D; Lundberg M and 4 more (2022) - Transparency Score: 2/6
Characteristics and predictors of off-label use of antipsychotics in general population sample.
Pirhonen E; Haapea M; Rautio N and 7 more (2022) - Transparency Score: 3/6
Childhood symptoms of attention-deficit/hyperactivity disorder and borderline personality disorder.
Tiger A; Ohlis A; Bjureberg J and 6 more (2022) - Transparency Score: 3/6
Childhood temperamental, emotional, and behavioral characteristics associated with mood and anxiety…
Bakken NR; Hannigan LJ; Shadrin A and 6 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST HN reported personal fees from Boehringer Ingelheim, Kyowa Kirin, ASKA Pharmaceutical, and Toyota Motor Corporation outside the submitted work. TAF reports grants and personal fees from Mitsubishi‐Tanabe, personal fees from MSD, personal fees from Shionogi, outside the submitted work. In addition, TAF has a patent 2018‐177688 concerning smartphone CBT apps pending, and intellectual properties for Kokoro‐app licensed to Mitsubishi‐Tanabe. All the other authors declare no competing interests."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025